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INTRODUCTION 
Evidence accumulated in recent years suggests that 
the nucleosome, the fundamental unit of chromatin 
and normal product of cell apoptosis, plays a key 
role in murine and human lupus as a major target 
autoantigen for autoantibody mediated tissue 
lesions1. The broad antinucleosome antibody family 
include; the nucleosome specific antibodies 
(antinucleosome antibodies without anti ds-DNA 
and antihistone reactivities), the antinucleosome 
antibodies with anti ds-DNA reactivity and the 
antinucleosome antibodies with antihistone 
reactivity2. Anti ds-DNA antibodies account for a 
minor part (<30%) of the serum antinucleosome 
reactivity in SLE patients and nucleosome specific 
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autoantibodies are in large excess over anti ds-DNA 
in SLE3. 
Antinucleosome specific antibodies have 
different genetic origin and pathogenic 
consequences compared with histone and ds-DNA 
specific antibodies4. In murine lupus, 
antinucleosome specific antibodies arise before the 
emergence of anti ds-DNA and antihistone 
antibodies and may be detected long before lupus-
prone mice produce pathogenic autoantibodies (Pre-
autoimmune mice)5.  
Lupus nephritis is an immune complex disease. 
Nucleosomes and possibly complement factor C1q 
may be the major players in its pathogenesis. 
Antinuclear antibody (ANA) complexed to 
nucleosomes can bind to heparan sulphate in the 
glomerular basement membrane via the histone part 
of the nucleosome6. Understanding the key role of 
the nucleosome will likely make possible new 
therapeutic interventions in SLE, such as tolerance 
induction to the subnucleosomal particles7. 
This study aimed to evaluate the frequency and 
specificity of antinucleosome autoantibodies in SLE 
patients and to study their relationship with disease 
activity and renal involvement. 
   
METHODS 
Study population: 
This case-control study was conducted on 26 
patients with SLE (22 females and 4 males) aged 
between 9 and 16 years (mean±SD: 13.5±2.5 
years). They were enrolled from the Pediatric 
Allergy and Immunology Unit of the Children's 
Hospital of Ain Shams University, meeting at least 
4 of the American Rheumatism Association 
Revised Criteria for diagnosis of SLE8. These 
patients were classified into two groups, the first 
group included fifteen patients with clinical renal 
involvement in the form of persistent proteinuria 
(more than 0.5 gm/day or more than 3+ by dipstick 
test) and/or cellular casts in urine (red blood cell, 
haemoglobin, granular, tubular or mixed)9. The 
second group comprised 11 patients with no clinical 
evidence of renal involvement based on normal 
results of urine analysis, serum creatinine and 
creatinine clearance. Patients without clinical renal 
involvement (group II) were followed up for one 
year by monthly microscopic urine analysis and 24 
hours urinary protein. Measurement of urinary 
microalbumin was repeated at the end of the study 
period and patients who had microalbuminurea 
were categorized as patients with subclinical lupus 
nephritis. All lupus patients underwent detailed 
history and clinical examination to calculate the 
total SLE activity score (SLEDAI)10. 
Twenty five out of the studied lupus patients 
(26) were receiving oral prednisolone (0.5-2 
mg/kg/day) either as monotherapy (n=15) or in 
combination with other immunosuppressive drugs, 
such as intravenous pulsed cyclophosphamide 
(n=7), or oral azathioprine (n=3). Only one patient 
was receiving azathioprine alone without 
prednisone. The cumulative dose of steroid therapy 
during the whole duration of the disease was 
calculated (from the patients' records). The dose of 
intravenous pulsed steroids was added. The average 
dose of steroids per square meter body surface area 
was calculated.  
In addition, 52 age- and sex- matched subjects 
were studied as a control group (group 3). They 
included 26 patients with juvenile rheumatoid 
arthritis "JRA" (22 females and 4 males), regularly 
followed-up at the Pediatric Allergy and 
Immunology Clinic, Children's Hospital, Ain 
Shams University (group 3A) after fulfillment of 
the American College of Rheumatology criteria for 
diagnosis of JRA 11. Their ages ranged between 9 
and 16 years (mean±SD = 13.5±2.4 years). Group 
3B included 26 healthy children (22 females and 4 
males) with no personal or family history of 
collagen vascular disease or renal disorders. Their 
ages ranged  between 9 and 16 years (mean±SD = 
13.6±2.5 years). 
 
Study measurements:  
Sampling  
Six milliliters of venous blood were collected. Four 
milliliters were transferred into a clean dry tube and 
left to clot. Prompt separation of serum was carried 
and used for direct assay of urea, creatinine, ANA, 
C3 and part of serum was stored at -20oC until 
assayed for of antinucleosome antibodies. The other 
two milliliters were collected on sodium citrate for 
erythrocyte sedimentation rate (ESR) measurement 
by Westergren method.  
Twenty-four hours urine was collected for 
determination of urinary creatinine, total protein 
and microalbumin. The urine was collected in 
sterile containers with no preservatives. It was 
stored at 2-8oC. On the other hand, complete urine 
analysis was done on a freshly collected sample.  
 
Assessment of serum and urinary creatinine:  
This was carried out on synchron CX7 autoanalyzer 
(Beckman instruments, Brea, California, USA) by 
modified rate Jaffe method12. The corrected 
creatinine clearance, according to the surface area, 
for every patient was then calculated as a 
percentage of the lowest normal value for age and 
sex. 
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Assessment of serum antinuclear antibodies (ANA) 
and C3:  
Serum ANA was detected by indirect 
immunofluorescence (IMMCO Diagnostics, 
USA)13. Estimation of serum C3 was done by 
quantitative determination by turbidimetry 
(Turbiquant C3, Behringwerke Diagnostics, 
Marburg, Germany)14.  
 
Determination of urinary total protein:   
Urinary protein was assayed applying timed end 
point method. Protein in the sample reacted with the 
pyrogallol red molybdate to form purple colour 
complex that had a maximum absorbance at 600 
nm. The assay was carried out using an automated 
analyzer (Synchron Cx7 system)15.  
 
Determination of urinary microalbumin: 
This was carried out using the turbitime analyzer. 
An undiluted urine sample was added to a buffer 
containing antibody specific for human serum 
albumin. The absorbance of the resulting turbid 
solution was proportional to the concentration of 
albumin in the sample urine. By constructing a 
standard curve from the absorbances of standards, 
the albumin concentration of the sample was 
determined 16. 
 
Determination of antinucleosome specific 
antibodies:  
This was performed by the ELISA technique 
(ORGENTEC, Carl-Zeiss-Strasse Mainz)17. 
Antibodies to highly purified human nucleosomes 
(antinucleosome specific antibodies), if present in 
diluted serum, would bind in the microwells. 
Washing of the microwells removes unbound serum 
antibodies. Horseraddish peroxidase (HRP) 
conjugated anti-human IgG immunologically binds 
to the bound patient antibodies forming a 
conjugate/antibody/antigen complex. Washing 
substrate in the presence of bound conjugate is 
hydrolyzed to form a blue colour. The addition of 
an acid stops the reaction forming a yellow end 
product. The intensity of this yellow colour is 
measured photometrically at 450 nm. The amount 
of colour is directly proportional to the 
concentration of IgG antibodies present in the 
original sample. Determination of antihistone 
antibodies and anti ds-DNA antibodies was based 
on the same principle 17. 
 
Interpretation of serum antinucleosome antibodies 
results  
As data distribution was non-parametric, serum 
antinucleosome antibodies levels were considered 
to be elevated if there levels were above the 95th 
percentile of the healthy control values (33.95 U/ml 
for antinucleosome specific antibodies, 39.3 U/ml 
for antihistone antibodies and 34.3 U/ml for anti ds-
DNA antibodies). 
 
Statistical analysis  
The results were analyzed by commercially 
available software package (StatView, Abacus 
concepts, Inc., Berkeley, CA, USA). The data were 
presented as mean and standard deviation, in 
addition to median and interquartile ranges (IQR). 
Non parametric data were analyzed by the Mann 
Whitney (z) test and the relationship between 
numeric variables was determined using the 
Spearman correlation  coefficient (r) test Chi-square 
test was used to compare qualitative variables. For 




Serum concentration of antinucleosome 
antibodies in the studied population and their 
relation to clinical lupus nephritis    
The three studied antinucleosome antibodies were 
significantly higher among lupus patients as 
compared to patients with JRA and healthy children 
(p<0.05 for the 3 antibodies). Meanwhile, patients 
with JRA had significantly higher values of both 
serum antinucleosome specific and anti ds-DNA 
antibodies than healthy controls. Although serum 
levels of antihistone antibodies of JRA patients 
were higher than that of healthy controls, the 
difference was statistically insignificant. Serum 
antinucleosome antibodies were significantly higher 
in lupus patients with clinical nephritis than patients 
without clinical nephritis (p<0.05 for the three 
antibodies). Table (1). 
 
Microalbuminuria in SLE patients without 
clinical renal involvement and its relation to 
antinucleosome antibodies seropositivity  
Initially, 4/11 (36.4%) of patients without clinical 
renal involvement had microalbuminuria. After a 
year of follow up, three more patients developed 
microalbuminurea as well. The 7 patients (63.6%) 
with microalbuminurea were considered to have 
subclinical lupus nephritis. All of them were 
seropositive for antinucleosome specific antibodies 
and three only were seropositive for antihistone and 
anti ds-DNA antibodies (Fig. 1). 
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Frequency of the antinucleosome antibodies 
among patients with SLE and JRA (pathological 
controls):  
The group of lupus patients as a whole and the 
subgroups with and without clinical renal 
involvement had significantly higher percentage of 
elevated antinucleosome specific antibodies than 
those with JRA (80.8%, 93.3% and 63.6% 
respectively vs 3.8%) (Fig. 2A). Meanwhile, only 
lupus patients with clinical renal involvement had 
significantly higher percentage of elevated 
antihistone antibodies (80%) than controls with 
JRA (46.2%). Results of the SLE patients compiled 
in one group (57.7%) and those of SLE patients 
who had no clinical renal involvement (27.3%) 
were comparable with JRA controls (Fig. 2B). On 
the other hand, the whole group of SLE (50%) and 
subgroup with clinical renal involvement (66.7%) 
had significantly higher percentage of elevated anti 
ds-DNA antibodies than subjects with JRA (7.7%). 
Results of lupus patients who had no clinical renal 
involvement (27.3%) were comparable to the JRA 
controls (Fig. 2C). 
 
Sensitivity, specificity and predictivity of 
antinucleosome antibodies for diagnosis of SLE 
and subclinical lupus nephritis: 
Antinucleosome specific antibodies had the highest 
sensitivity, specificity and predictive values for 
SLE. Anti ds-DNA antibodies had higher 
specificity and predictive values than antihistone 
antibodies for SLE, while antihistone antibodies 
had higher sensitivity for SLE than anti ds-DNA 
antibodies. On the other hand,  antinucleosome 
specific antibodies had higher sensitivity, 
specificity and predictive values for early diagnosis 
of subclinical renal involvement in SLE than 
antihistone and anti ds-DNA antibodies (table 2). 
 
Renal involvement in relation to antinucleosome 
antibodies' seropositivity:  
All seropositive patients for one or more of the 
antinucleosome antibodies had lupus nephritis 
(either clinical or subclinical). On the other hand, 
lupus nephritis (either clinical or subclinical) was 
diagnosed in 20%, 63.5% and 69.2% of 
antinucleosome specific, antihistone and anti ds-
DNA seronegative patients respectively. All anti ds-
DNA and antihistone seronegative lupus patients 
with nephritis were seropositive for anti 
nucleosome specific antibodies (table 3). 
 
Correlation analyses 
The recorded values of SLEDAI of SLE patients 
correlated positively to serum ANSAb, serum 
AHAb and serum anti ds-DNA antibodies (r= 0.97, 
0.99 and 0.97, respectively, p < 0.05). Also, the 
recorded cumulative steroid doses of SLE patients 
showed significant positive correlations with serum 
ANSAb, serum AHAb and serum anti ds-DNA 
antibodies (r= 0.5, 0.6 and 0.6, respectively, p < 
0.05). Also, values of creatinine clearance of SLE 
patients showed significant negative correlations 
with  serum ANSAb, serum AHAb and serum anti 
ds-DNA antibodies (r= 0.87, 0.85 and 0.82, 
respectively, p < 0.05). 
 
 
ANSAb: antinucleosome specific antibodies, AHAb: antihistone antibodies, 
AdsDNAAb: antidouble staranded DNA antibodies.  
 
Figure 1.  Percentage of elevated antinucleosome antibodies among the 
seven patients with subclinical nephritis.  


































































































































































































































ANSAb: antinucleosome specific antibodies, AHAb: antihistone antibodies, AdsDNAAb: antidouble staranded DNA antibodies.  
Figure 2. Percentage of patients with elevated  antinucleosome antibodies in  the studied groups 
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Table 1. Comparison between lupus patients and controls in serum levels of antinucleosome antibodies 
    
 ANSAb (U/mL) Antihistone Ab (U/ml) Anti ds-DNA Ab (U/ml) 





















































































































































































































Table 2. Sensitivity, specificity and predictive values of antinucleosome antibody family for 
diagnosis of SLE and subclinical lupus nephritis. 
 Sensitivity  Specificity  Positive predictive 
value  
Negative 
predictive value  
SLE  Subclinical 
nephritis  
SLE  Subclinical 
nephritis  
SLE  Subclinical 
nephritis  
SLE  Subclinical 
nephritis  
ANSAb 80.8% 100% 96.2% 100% 95.4% 100% 83.3% 100% 
AHAb 57.7% 43% 53.8% 100% 55.6% 100% 56% 50% 
AdsDNAAb 50% 43% 92.3% 100% 86.6% 100% 64.8% 50% 
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Table 3. Renal involvement in relation to antinucleosome antibodies seropositivity  











































Nucleosomes are generated in vivo by the process 
of  apoptosis which is disturbed in SLE. 
Nucleosomes are the major target autoantigens for 
autoantibodies mediating tissue lesions, especially 
glomerulonephritis in SLE18. In the present study, 
all SLE patients had significantly higher serum 
levels of the three antinucleosome antibodies 
(antinucleosome specific, antihistone and anti ds-
DNA antibodies) than both healthy controls and 
patients with JRA. Seropositivity for at least one of 
the three studied members of the antinucleosome 
antibody family was elicited in 84.6% of our 
studied SLE patients. These results are in 
accordance with previous studies which have 
reported that antinucleosome antibody reactivity is 
a very sensitive marker of SLE3,19,20,21. In addition, 
27.3% of our  26 lupus patients had elevated 
antinucleosome specific antibody level only. 
Similarly, it has been reported that 30% of SLE 
patients with high antinucleosome specific antibody 
reactivity have little, if any, anti ds-DNA or 
antihistone reactivity21.  
The mechanisms that lead to the induction of 
antinucleosome autoantibodies in SLE remain 
obscure. In view of the prominence of nucleosomes 
which circulate at high levels in approximately one 
third of patients with SLE22, it  has been speculated 
that highly accelerated rates of apoptosis23, and/or 
abnormal sites or abnormal  processing of apoptotic 
cells could  lead to autoantibody production24. Also, 
nucleosomes may elicit the production of 
interleukin-6 and stimulation of lympho-
proliferation and IgG synthesis by splenic B cells. 
This could result in a polyclonal activation that 
triggers both a specific (nucleosome-driven) and 
non specific antibody production22. An important 
clue  for the etiopathogenic role of antinucleosome 
antibodies in SLE is our  finding of a significant 
positive correlation between SLEDAI and the 3 
antinucleosome antibodies, this denotes that serum 
antinucleosome antibodies; reflect disease activity 
in SLE patients. Amoura and associates3 have 
reported that antinucleosome antibody titres were 
positively correlated closely with the SLEDAI 
score. 
In the present study, the antinucleosome 
specific antibodies had a sensitivity of 80.8% for 
the diagnosis of SLE. In previous studies, the 
reported sensitivities were 71.7% and 76% 
respectively3,25. We also found that the 
antinucleosome specific antibodies had an excellent 
specificity for the diagnosis of SLE (96.2%). Bruns 
and associates26 assumed that antinucleosome 
specific antibodies were highly specific for the 
disease (97%) and superior to anti ds-DNA 
antibodies. Antihistone antibodies had lower 
sensitivity (57.7%) and specificity (53.8%) for SLE 
than antinucleosome specific antibodies. This low 
specificity might be due to the presence of high 
percentage of antihistone antibody seropositivity 
among JRA patients (46.2%) while 3.8% and 7.7% 
only of JRA patients were seropositive for 
antinucleosome specific and anti ds-DNA 
antibodies respectively. In addition, our data 
revealed that anti ds-DNA antibodies had a much 
lower sensitivity (50%) for SLE than both 
antinucleosome specific and antihistone antibodies. 
In contrast, it had a better specificity (92.3%) for 
SLE. In other reports27,28, the sensitivity for anti ds-
DNA antibodies in SLE ranged between 50% and 
70%.  
Renal disease is a common manifestation of 
SLE. Although the multiple immunologic 
abnormalities of lupus can affect any organ system, 
involvement of the kidneys is often a major source 
of patient's morbidity and mortality29. In the present 
study, lupus patients with clinical nephritis had 
significantly higher levels and seropositivity 
percentage of the three antinucleosome antibodies 
than patients without clinical nephritis. These 
findings indicate that antinucleosome antibodies 
might be reliable indicators of lupus nephritis. This 
assumption is supported by the results of Amoura 
and associates3 who revealed that patients with 
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active lupus nephritis had significantly higher 
percentage of antinucleosome antibody 
seropositivity than patients with active SLE but 
without nephritis. 
It has long been known that in absence of 
clinical evidence of renal disease, excess urinary 
excretion of microalbumin could indicate 
subclinical nephropathy and its measurement may 
have a role in the early diagnosis and subsequent 
monitoring of renal disease in SLE 30. In the present 
work, 7 out of the 11 studied patients without 
clinical renal involvement had microalbuminuria 
i.e. subclinical nephritis and were antinucleosome 
specific antibody seropositive. In contrast, 
seropositivity for antihistone and anti ds-DNA 
antibodies was demonstrated in 3 patients only. 
Therefore, both antihistone and anti-ds DNA 
antibodies had a much lower sensitivity (43%) than 
antinucleosome specific antibodies (100%) for early 
diagnosis of sublinical lupus nephritis. This notion 
is supported by the presence of high  levels of 
antinucleosome specific antibodies among patients 
who were initially free of microalbuminuria and 
were seronegative for both antihistone and anti-
dsDNA antibodies. Actually, positive results for 
antinucleosome specific antibodies preceded the 
occurrence of microalbuminurea in those patients. 
Previous studies showed that antinucleosome 
specific antibodies appear before anti ds-DNA and 
antihistone antibodies and persist later in the course 
of the disease, along with the development of anti 
ds-DNA and antihistone antibodies7. These data are 
in agreement with current finding of an excellent 
sensitivity, specificity and predictivity for 
antinucleosome specific antibody in the early 
diagnosis of subclinical lupus nephritis (100%). 
Also, our results  showed that 9 out of the 13 (69%) 
anti ds-DNA seronegative lupus patients were 
seropositive for antinucleosome specific antibodies, 
and 7 out of the 11 (63.6%) antihistone antibodies 
seronegative patients were seropositive for 
aninucleosome specific antibodies. Interestingly, all 
patients who were seropositive for antinucleosome 
specific antibodies and in the same time 
seronegative for either antihistone or anti ds-DNA 
antibodies showed some evidence of nephritis 
whether clinical or subclinical. This might suggest 
that the detection of anti-nucleosome specific 
antibodies could be a useful predictor of renal 
involvement  specially among anti ds-DNA 
serongative lupus patients.  
An interesting observation was the absence of 
renal involvement, whether clinical or subclinical, 
among the 4 lupus patients who were seronegative 
for the three antinucleosome antibodies during one 
year of follow up. It is hypothesized that when one 
or more of the antinucleosome antibodies is 
positive, this may be an index of renal involvement 
but when the 3 antinucleosome antibodies are 
negative, lupus nephritis may not be expected. The 
findings are of course limited by the sample size. 
Large scale studies are needed to verify this 
observation.  
In the present work, there was a significant 
negative correlation between the three 
antinucleosome antibodies and creatinine clearance 
and a significant positive correlation between them 
and the cumulative dose of steroids. This means 
that the extent of the elevation of serum 
antinucleosome antibodies was closely linked to the 
severity of lupus nephritis as assessed by creatinine 
clearance and cumulative steroid dose. The 
relationship of antinucleosome antibodies to the 
severity of lupus nephritis is possibly a causal one 
in which these antibodies might not only play a role 
in the pathogenesis of lupus nephritis but also 
determine its clinical severity. 
In conclusion, the observed sensitivity and 
specificity of antinucleosome specific antibodies as 
early indicators of subclinical lupus nephritis, 
especially in anti ds-DNA seronegative lupus 
patients, appear encouraging and deserve further 
analysis on a large sample of lupus patients in order 
to confirm the validity of these antibodies as early 
indicators of subclinical nephritis. 
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